Ph-like acute lymphoblastic leukemia
|
|
- Charity Short
- 6 years ago
- Views:
Transcription
1 OPTIMIZING TREATMENTS FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: WHAT IT TAKES TO MOVE THE NEEDLE Ph-like acute lymphoblastic leukemia Thai Hoa Tran 1 and Mignon L. Loh 1,2 1 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA; and 2 Department of Pediatrics, UCSF Benioff Children s Hospital, San Francisco, CA Philadelphia chromosome like acute lymphoblastic leukemia (Ph-like ALL) is a newly identified high-risk (HR) B-lineage ALL subtype, accounting for ~15% of children with National Cancer Institute defined HR B-ALL. It occurs more frequently in adolescents and adults, having been reported in as much as 27% of young adults with ALL between 21 and 39 years of age. It exhibits adverse clinical features, confers a poor prognosis, and harbors a diverse range of genetic alterations that activate cytokine receptor genes and kinase signaling pathways, making it amenable to treatment with tyrosine kinase inhibitor (TKI) therapy. Multiple groups are currently conducting clinical trials to prospectively screen patients with Phlike ALL and incorporate the relevant TKI for those harboring ABL-class gene rearrangements or those with JAK-STAT pathway alterations. The success of combinatorial treatment of TKI with chemotherapy in the setting of Ph-positive ALL suggests that this approach may similarly improve outcomes for patients with Ph-like ALL. Hence, Ph-like ALL illustrates the modern treatment paradigm of precision medicine and presents unique opportunities for harnessing international collaborations to further improve outcomes for patients with ALL. Learning Objectives To recognize the clinical features and outcomes of Ph-like ALL To understand the molecular hallmarks of Ph-like ALL To describe the different Ph-like ALL subgroups and their therapeutic implications Introduction Acute lymphoblastic leukemia (ALL) is the commonest childhood cancer and undoubtedly portrays a true success story in the field of pediatric oncology. Since the 1960s, overall survival rates for children with ALL have risen from,10%tonearly90%. 1 This drastic outcome improvement stems from the efficacy of a multiagent chemotherapy regimen, better risk stratification as a result of the improved understanding of the biology of the leukemia, and careful monitoring of minimal residual disease as a measure of treatment response. 2 Nevertheless, relapse still occurs in 15% to 20% of patients, and outcomes are dismal after relapse, making ALL the leading cause of cancer-related death among children and young adults. 2,3 Over the last decade, advances in cancer genomics have shed important insights into our current understanding of the genomic landscape of ALL and have provided the rationale for novel therapeutic targets to expand the paradigm of precision medicine to this disease. Although ALL genomes are relatively silent compared with other tumor types, 4 ALL is characterized by recurrent alterations that carry prognostic significance, allowing for subdivision of ALL into distinct genetic subtypes. The spectrum of these genetic alterations includes aneuploidy, copy number changes, sequence mutations, and chromosomal rearrangements that deregulate gene expression or result in the formation of chimeric fusion proteins. 5 Recent large-scale genomic profiling and sequencing studies have led to important discoveries that deepen our understanding of the relationship between gene mutations, outcomes, and potential therapeutic interventions. One example is the identification of a particular subtype of B-ALL that is associated with a high risk of relapse, displays a gene expression profile (GEP) similar to that of Philadelphia (Ph) chromosome positive ALL, and frequently harbors IKZF1 alterations, but lacks the hallmark BCR-ABL1 oncoprotein, thus known as Ph-like ALL. 6-8 This review will highlight the most up-to-date knowledge on Ph-like ALL from the clinical, biologic, and therapeutic perspectives. Ph-like ALL: the clinical picture Ph-like ALL comprises 10% of children with standard-risk (SR) B-lineage ALL (age,10 years or white blood cell count #50 000/uL at diagnosis) and 15% of children who present with National Cancer Institute (NCI) defined HR B-ALL (age.10 years or white blood cell count $50 000/uL at diagnosis). 6 Its frequency increases with age, rising to 21% in adolescents and up to 27% in young adults with B-ALL. 6 It is almost 3 times more common than Ph-positive ALL. In contrast to the rising incidence of Ph-positive ALL with age, the incidence of Ph-like ALL seems to peak in adolescents and young adults, and decreases to,10% in older adults between the ages of 40 and 85, as reported in a single German cohort. 9 However, recent genomic profiling data from a larger multicentered cohort of.600 adults with B-ALL confirms the high frequency of Ph-like ALL within this population, estimated to be 20% in adults aged 40 to 79 years. 10 Males are more commonly affected than females across all age groups, with a male-to-female ratio of 1.5:1 among children, and rising to 4:1 among young adults. 6 Ph-likeALLseemstohaveapredilection among patients of Hispanic descent, which could be partly explained by the high association of CRLF2 rearrangements within this ethnic group. 11 Moreover, a recent genome-wide association study identified an inherited susceptibility locus for Ph-like ALL within Conflict-of-interest disclosure: The authors declare no competing financial interests. Off-label drug use: Use of TKIs in Ph-like ALL patients with kinase-activating lesions. Hematology
2 the GATA3 gene (rs ), which is also markedly more common in patients of Hispanic ethnicity and Native American genetic ancestry. 12 Patients with Ph-like ALL often exhibit adverse clinical features. These patients generally present with an initial leukocyte count /uL at diagnosis and elevated minimal residual disease at the end of induction therapy compared with patients with non Ph-like ALL. 6 Notably, high levels of end-of-induction MRD and induction failures appear to be particularly common in Ph-like cases harboring the EBF1-PDGFRB fusion. 13 In a multivariable analysis, the presence of a Ph-like GEP constitutes an independent negative prognostic factor. 14 This is further supported by the inferior outcomes of Ph-like ALL patients compared with non Ph-like ALL across all age groups, with a dismal prognosis for young adults with Ph-like ALL (Figure 1). 6 Among adolescents with Ph-like ALL, outcomes remain inferior compared with those with other high-risk ALL subtypes such as KMT2A-rearranged ALL and Ph-positive ALL. In the Children s Oncology Group s (COG) most recently completed phase 3 randomized controlled trial for HR-ALL, AALL0232, the 5-year event-free survival rate for Ph-like cases was 63% compared with 86% for non Ph-like cases. 14 Importantly, the outcome differences were maintained regardless of the randomized treatment arm for patients with Ph-like ALL, whereas for patients with non Ph-like ALL, this study demonstrated the superiority of high-dose methotrexate over Capizzi-style methotrexate in the first interim maintenance phase. Outcome differences also exist between different Ph-like ALL subgroups, with JAK2 and EPOR rearrangements having the worst outcome, and Ph-like cases with IKZF1 alteration faring worse than those without IKZF1 alteration. 6 Despite the overall poor outcomes in Ph-like ALL, one singleinstitution study reported comparable outcomes with that of patients with non Ph-like ALL using an MRD-based risk-directed treatment intensification approach. 15 However, the study population was small, with different clinical and biologic characteristics, compared with previous published pediatric Ph-like ALL cohorts, and a significantly higher proportion of patients were treated with hematopoietic stem cell transplantation. Ph-like ALL: the genomic landscape The identification of the Ph-like ALL subset has led to multicollaborative genomic profiling efforts intended to gain insights into the biology of this disease. A recent comprehensive genomic analysis of 154 Ph-like ALL samples generated via different next-generation sequencing platforms, including transcriptome, whole-exome, and whole-genome sequencing, has deciphered the heterogeneous nature of the genomic landscape. 9 Despite its complexity, the common molecular hallmark of Ph-like ALL constitutes a myriad of genetic alterations that activate cytokine receptor genes and kinase-signaling pathways, providing the rationale for the use of targeted therapies in this subtype. These alterations can be subdivided into 5 distinct subgroups based on the type of cytokine receptor or kinase fusion present: (1) rearrangements of CRLF2, (2) ABL-class gene rearrangements, (3) JAK2 and EPOR rearrangements, (4) sequence mutations or deletions activating JAK-STAT- or MAPK signaling pathways, and (5) other rare kinase alterations (Figure 2; Table 1). 6,16,17 CRLF2 rearrangements that result in its overexpression represent the most prevalent alteration in Ph-like ALL, accounting for 47% cases. 6 The CRLF2 gene at locus Xp22.3/Yp11.3 encodes the thymic stromal lymphopoetin receptor and heterodimerizes with the IL-7R a-chain to bind its ligand, thymic stromal lymphopoietin (TSLP), leading to downstream Figure 1. Outcomes of children, adolescents, and young adults with Ph-like ALL. (A) Patients with Ph-like ALL have an inferior outcome compared with patients with non Ph-like patients treated on AALL0232. (B) Among patients with Ph-like ALL, young adults have the worst prognosis compared with children and adolescents. Adapted from Roberts et al 6 and Loh et al, 14 with permission. signaling that mediates processes such as lymphopoiesis, allergic reaction, and inflammation. 18 Three mechanisms of CRLF2 deregulation have been described: (1) translocation of CRLF2 to the immunoglobulin heavy-chain transcriptional enhancer (14q32.3; IGH@-CRLF2); (2) a focal interstitial deletion of the pseudoautosomal region of the sex chromosomes (Xp22.23 or Yp11.32) centromeric to CRLF2, resulting in the fusion of CRLF2 to the G-protein purinergic receptor P2RY8 gene (P2RY8-CRLF2); and (3) the less common activating CRLF2 point mutation F232C. 16,19,20 In addition to Ph-like ALL, CRLF2 rearrangements are frequently observed in Down syndrome associated ALL and are age dependent, with P2RY8-CRLF2 rearrangements occurring more commonly in younger patients, whereas IGH@-CRLF2 predominate among adolescents and young adults, particularly those of Hispanic ancestry. 19,20 Moreover, half of CRLF2-rearranged cases harbor concomitant JAK mutations, the most common of which is the R683G point mutation located in the pseudokinase domain of JAK2. 19,21, American Society of Hematology
3 18% 2 16% 2% 2% 8% 15% 13% 2% 42% 1 5% 1 18% 8% 18% 1 6% 37% Childhood HR Adolescent Young adult CRLF2 -rearranged, JAK2 mutant CRLF2-rearranged, JAK2 wild-type ABL1-class rearrangements JAK2 rearrangements EPOR rearrangements Other JAK-STAT alterations Ras alterations Unknown Other kinase lesion Figure 2. Distribution of Ph-like ALL subgroups among children, adolescents, and young adults. CRLF2 rearrangements are the most prevalent genetic alteration across all age groups. ABL-class gene rearrangements are more frequent in childhood, whereas there is a striking increase in the frequency of JAK2 rearrangements among young adults with Ph-like ALL. HR, high-risk. Adapted from Roberts et al, 6 with permission. The second major subgroup, comprising 13% of Ph-like ALL, involves rearrangements of ABL-class genes such as ABL1, ABL2, PDGFRB, andcsf1r. 6,17 Multiple fusion partners have been identified for each one of these; but all fusions conserve the intact kinase domain of the carboxyl terminal of the ABL-class gene juxtaposed in frame to the amino terminal of the partner gene. JAK2 and EPOR rearrangements together constitute 11% of Ph-like ALL, but there is a remarkable increase in the prevalence of JAK2 fusions among young adults compared with that in children and adolescents (~15% vs 5%, respectively). 6,16 In Ph-like ALL, JAK2 represents a promiscuous gene with 10 different reported fusion partners. EPOR rearrangements have been identified in ~ of Ph-like ALL. Four types of EPOR rearrangements have been described, with each type involving the juxtaposition of the EPOR gene to the enhancer regions of immunoglobulin heavy or k loci, leading to the deregulated expression of a truncated form of EPOR that has been shown to drive leukemogenesis. 23 Both JAK2 and EPOR rearrangements lead to constitutive activation of JAK-STAT signaling pathways, which can be abrogated in vitro and in some preclinical xenograft models by the use of JAK inhibitors such as ruxolitinib. 6,17,23,24 Other than kinase fusions, sequence mutations and focal deletions of genes leading to activation of the JAK-STAT pathway are present in 13% of Ph-like ALL. 6 The spectrum of alterations within this subgroup includes mutations of IL7R, FLT3, and IL2RB that constitutively activate these cytokine receptors, activating mutations within the JAK kinases themselves (JAK1 and JAK3), and deletion of genes that encode negative regulators of the JAK-STAT pathway (SH2B3). Point mutations in the JAK kinases are usually accompanied by rearrangements of CRLF2, whereas IL7R mutations arise mostly within the transmembrane domain to promote constitutive JAK-STAT signaling. Ras pathway mutations occur in of patients with Ph-like ALL; these include activating mutations of NRAS, KRAS, PTPN11, and NF1, which have also been reported in other ALL subtypes such as hypodiploid ALL, 25 KMT2A-rearranged ALL, 26 and relapsed ALL. 26 Rare kinase fusions involving NTRK3 and DGKH occur in 0.9% of Ph-like ALL. Kinase-activating lesions were not identified in the remaining 5% of Ph-like ALL. Although still considered to be Ph-like, the GEP of patients with kinase fusions (ABL-class, JAK2, andepor rearrangements) is distinct from those with other JAK-STAT or Ras pathway alterations. Finally, similarly to Ph-positive ALL, a unifying hallmark of Ph-like ALL is the high frequency of IKZF1 alterations relative to BCR- ABL1 negative non Ph-like ALL (68% vs 16%, P,.001). IKZF1 alterations occur more frequently in patients with Ph-like ALL, harboring a kinase fusion than in those with a sequence mutation (78% vs 33%, P,.001). 6 Ph-like ALL: therapeutic opportunities for precision medicine trials The recently characterized genomic landscape of Ph-like ALL has revealed a diverse array of targetable kinase-activating lesions that are Hematology
4 Table 1. Repertoire of kinase rearrangements in Ph-like ALL along with their partner genes and potential therapeutic targets Kinases 59 partner genes (number of patients) Potential TKI Clinical trials ABL1 ETV6 (3), NUP214 (6), RCSD1 (1), RANBP2 (1), SNX2 (1), ZMIZ1 (2) Dasatinib AALL1131 ABL2 PAG1 (1), RCSD1 (4), ZC3HAV1 (2) Dasatinib AALL1131 PDGFRB EBF1 (6), SSBP2 (1), TNIP1 (1), ZEB2 (1) Dasatinib AALL1131 CSF1R SSBP2 (4) Dasatinib AALL1131 CRLF2 IGH (19), P2RY8 (11) Ruxolitinib AALL1521 JAK2 ATF7IP (1), BCR (2), EBF1 (1), ETV6 (2), PAX5 (7), PPFIBP1 (1), SSBP2 (2), Ruxolitinib AALL1521 STRN3 (1), TERF2 (1), TPR (1) EPOR IGH (7), IGK (2) Ruxolitinib AALL1521 TSLP IQGAP2 (1) Ruxolitinib AALL1521 IL2RB MYH9 (1) JAK1/JAK3 inhibitor N/A TYK2 MYB (1) TYK2 inhibitor N/A NTRK3 ETV6 (1) Crizotinib N/A PTK2B KDM6A (1), STAG2 (1) FAK inhibitor N/A DGKH ZFAND3 (1) Unknown N/A Adapted from Roberts et al, 6 with permission. amenable to tailored kinase inhibitor therapy. Despite its genetic complexity, the majority of Ph-like ALL cases have a targetable lesion involving the ABL or JAK-STAT signaling pathways. Extensive in vitro and ex vivo data have provided compelling evidence to incorporate relevant TKIs in combination with chemotherapy in this ALL subtype. A priori, all ABL-class fusions such as ABL1, ABL2, PDGFRB, and CSF1R rearrangements exhibit exquisite sensitivity to ABL inhibitors (imatinib or dasatinib), whereas JAK2/EPOR rearrangements as well as other activating mutations of the JAK-STAT pathway can be inhibited by JAK inhibitors (eg, ruxolitinib) in both murine pre B cell lines and patient-derived xenograft models. 6,17,27 CRLF2-rearranged Ph-like ALL demonstrates hyperactive JAK- STAT, PI3K, mtor, and BCL2 signaling, and therapies targeting these pathways are currently being investigated in preclinical and clinical studies. 18,27,28 Other rare kinase alterations in Ph-like ALL can also be targeted by crizotinib, FAK inhibitors, and TYK2 inhibitors for NTRK3, PTK2B,andTYK2 fusions, respectively. 6 Coupled with these data suggesting the efficacy of TKI therapy are anecdotal reports of patients with Ph-like ALL harboring the EBF1-PDGFRB fusion who have sustained durable responses after treatment with ABL inhibitors in combination with conventional chemotherapy. 6,29 In light of the dramatic survival improvement of Ph-positive ALL upon the incorporation of imatinib with chemotherapy, 30 the aforementioned lines of evidence provide a strong rationale for the prospective investigation of the efficacy of combinatorial treatment of TKI and chemotherapy in Ph-like ALL with targetable lesions. Given the heterogeneity of Ph-like ALL, translation of genomic discoveries into pragmatic real-time clinical algorithms can be challenging. Several pediatric consortiums have adopted different strategies to screen for Ph-like ALL patients to modify their therapy with the relevant TKI. St. Jude s Children s Research Hospital uses a next-generation sequencing platform to screen for all patients newly diagnosed with ALL to identify those with Ph-like ALL, whereas the UK group focuses their screen on ABL-class fusions in patients who respond poorly to therapy defined as induction failure, positive MRD at day 28, or persistent MRD at week COG has incorporated an algorithm to screen for the Ph-like GEP among all newly diagnosed NCI HR B-ALL patients using a well-validated low-density array card (Figure 3). 6,31 Those positively screened for Ph-like GEP during induction will undergo additional genetic testing to identify the associated kinase lesion. Subsequently, dasatinib will be initiated at the beginning of consolidation therapy on a modified BFM-based chemotherapy backbone for patients harboring ABL-class fusions on the current phase 3 trial for HR-ALL, AALL1131. Furthermore, the phase 2 AALL1521 trial aims to determine the optimal dosage of ruxolitinib in combination with chemotherapy, and in addition will assess the efficacy of this combinatorial regimen in Ph-like ALL patients with CRLF2 rearrangements and/or other JAK-STAT pathway alterations. The lack of a uniform molecular definition of Ph-like ALL may account for the variability in the reported frequencies of various genetic lesions. However, it should be emphasized that the ultimate goal is to therapeutically target the underlying kinase lesion rather than identify the Ph-like signature that clusters them. This can be achieved through different approaches, from standard reversetranscription polymerase chain reaction, fluorescence in situ hybridization, phosphoflow signaling analysis, NanoString assay, or other next-generation genome sequencing techniques, each of which is being pursued actively by different groups of investigators. Other Ph-like subgroups such as those harboring NTRK3 fusions or Ras pathway mutations are infrequent, precluding the possibility of designing a dedicated trial for these lesions. However, because Ras mutations represent a hallmark of near-haploid ALL 25 and are frequently found in relapsed ALL, 32 one could envision the inclusion of this subgroup into a larger trial designed to study other Ras-mutated ALL subtypes. Direct oncogenic Ras inhibition remains challenging, but targeting downstream Ras pathway effectors such as MEK has demonstrated significant promise and is currently being evaluated prospectively in early-phase trials. 32 The ALK inhibitor, crizotinib, is currently being used as up-front therapy or in the setting of disease relapse for several solid tumor types. 33 However, one ongoing challenge lies in the integration of these novel therapies into the existing ALL chemotherapy backbone. In addition to the aforementioned TKIs, other novel molecular targets have shown promise in preclinical models, suggesting their potential therapeutic application to Ph-like ALL. First, inhibition of heatshock protein 90 (HSP90), a molecular chaperone that promotes the degradation of wild-type or mutant JAK2 by AUY922 or PU-H71, has demonstrated efficacy in inhibiting proliferation and suppressing downstream signaling in CRLF2-rearranged or JAK-mutant ALL cell lines in addition to murine models that became insensitive to JAK inhibitors or acquired therapy-resistant kinase domain mutations after JAK inhibition. 34,35 This serves as a proof-of-concept for further evaluation of HSP90 inhibition combined with JAK inhibitors or other ALL therapies in JAK-dependent ALL. Moreover, preclinical efficacy of retinoids in IKZF1-mutated BCR-ABL1 cell 564 American Society of Hematology
5 Figure 3. Testing algorithm for Ph-like ALL in COG trials. COG, Children s Oncology Group; LDA, low-density array; mpcr, multiplex polymerase chain reaction; spcr, singleplex polymerase chain reaction. Courtesy of Shalini Reshmi, Cytogenetics/Molecular Genetics Laboratory, National Children s Hospital, Columbus, OH. lines and patient-derived xenograft models have been recently described. 36 IKZF1 alterations drive stem cell renewal, cause abnormal bone marrow adhesion, and result in decreased TKI sensitivity. Retinoids have been shown to reverse this phenotype and potentiate TKI activity in IKZF1-altered mouse and human BCR-ABL1 ALL. Altogether, HSP90 inhibitors and retinoids represent potential therapeutic candidates given the prevalence of JAK-STAT pathway and/or IKZF1 alterations in Ph-like ALL. Conclusions and future directions Ph-like ALL is a newly identified ALL subtype defined by its unique GEP, which is associated with a poor prognosis. Given the high prevalence of targetable kinase-activating lesions identified in patients with Ph-like ALL, there is compelling evidence from both experimental models and clinical observations for the use of relevant TKIs in combination with conventional chemotherapy. Although Phlike ALL is 3 times more common than Ph-positive ALL, its genetic heterogeneity represents a limiting factor to develop well-designed, statistically powered, randomized controlled trials to establish TKI efficacy for each distinct subset (ABL-class vs JAK-dependent subgroups). This highlights the need to harness international collaborations to systematically study rare, high-risk disease entities to improve outcomes. Successful examples of such international collaborative efforts include studies of KMT2A-rearranged infant ALL and Ph-positive ALL. 37 In view of these potential global collaborations, different screening strategies for Ph-like ALL should be standardized among different groups to ensure comparable outcomes. In parallel, future challenges in Ph-like ALL should also focus on investigating mechanisms of resistance, as we learned from the adult chronic myeloid leukemia and Ph-positive ALL experiences regarding the emergence of drug-resistant kinase domain mutations after long-term TKI exposure. 38 In vitro saturation mutagenesis screens of Ba/F3 murine cells harboring EBF1-PDGFRB have identified the analogous ABL1 T315I gatekeeper kinase domain (KD) mutation T681I in the majority of dasatinib-resistant clones. 39 Furthermore, the recent case report of disease relapse mediated by the T315I KD mutation in a Ph-like ALL patient harboring the ETV6- ABL1 fusion after treatment with dasatinib demonstrates the need for future studies investigating mechanisms of acquired resistance and identifying novel therapies in the relapsed setting. 40 Finally, Ph-like ALL illustrates the new paradigm of how genomic discoveries translate into novel therapeutic avenues in the era of precision medicine and presents new opportunities to improve outcomes in high-risk subsets of B-ALL. Correspondence Mignon Loh, Loh Laboratory, Helen Diller Family Comprehensive Cancer Center, Box 3112, rd St, Room 284, San Francisco, CA 94158; mignon.loh@ucsf.edu. References 1. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16): Hunger SP, Loh ML, Whitlock JA, et al; COG Acute Lymphoblastic Leukemia Committee. Children s Oncology Group s 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013; 60(6): Raetz EA, Bhatla T. Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Hematol Am Soc Hematol Educ Program. 2012;2012: Ma X, Edmonson M, Yergeau D, et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun. 2015;6: Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125(26): Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014; 371(11): Hematology
6 7. Mullighan CG, Su X, Zhang J, et al; Children s Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5): Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2): Herold T, Baldus CD, Gökbuget N. Ph-like acute lymphoblastic leukemia in older adults. N Engl J Med. 2014;371(23): Roberts KG, Payne-Turner D, McCastlain K, et al. High frequency and poor outcome of Ph-like acute lymphoblastic leukemia in adults. Poster presented at the 57 th ASH Annual Meeting & Exhibition, December 6 th, Orlando, FL. 11. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/ Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26): Perez-Andreu V, Roberts KG, Harvey RC, et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet. 2013;45(12): Schwab C, Ryan SL, Chilton L, et al. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood. 2016;127(18): Loh ML, Zhang J, Harvey RC, et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children s Oncology Group TARGET Project. Blood. 2013;121(3): Roberts KG, Pei D, Campana D, et al. Outcomes of children with BCR- ABL1 like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014;32(27): Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol. 2015;12 (6): Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22(2): Tasian SK, Doral MY, Borowitz MJ, et al. Aberrant STAT5 and PI3K/ mtor pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood. 2012;120(4): Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11): Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13): Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2009; 106(23): Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115(5): Iacobucci I, Li Y, Roberts KG, et al. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell. 2016; 29(2): Maude SL, Dolai S, Delgado-Martin C, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015;125(11): Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3): Tasian SK, Loh ML, Hunger SP. Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. Cancer. 2015;121(20): Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mtor in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012;120(17): Waibel M, Solomon VS, Knight DA, et al. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Reports. 2013;5(4): Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRBpositive acute lymphoblastic leukemia. J Clin Oncol. 2013;31(25): e413-e Schultz KR, Carroll A, Heerema NA, et al; Children s Oncology Group. Long-term follow-up of imatinib in pediatric Philadelphia chromosomepositive acute lymphoblastic leukemia: Children s Oncology Group study AALL0031. Leukemia. 2014;28(7): Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010; 116(23): Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23): Ferguson M, Hingorani P, Gupta AA. Emerging molecular-targeted therapies in early-phase clinical trials and preclinical models. Am Soc Clin Oncol Educ Book. 2013: Weigert O, Lane AA, Bird L, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012;209(2): Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22): Churchman ML, Low J, Qu C, et al. Efficacy of Retinoids in IKZF1- Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell. 2015;28(3): Pui CH, Yang JJ, Hunger SP, et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015;33(27): DeBoer R, Koval G, Mulkey F, et al. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph1) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) and Leuk Lymphoma. 2016: Tran TH, Nguyen JV, Smith CC, et al. Identifying drug-resistant mutations in EBF1-PDGFRB Ph-like ALL. Poster presented at the 57th ASH Annual Meeting & Exposition, 5 December Orlando, FL. 40. Yeung DT, Moulton DJ, Heatley SL, et al. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. Leukemia. 2015;29(1): American Society of Hematology
BCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos
BCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos Ph like ALL BCR ABL1 like acute lymphoblastic leukemia (ALL)
More informationPh-like (BCR/ABL1-like): un apporoccio baato sul target molecolare
Ph-like (BCR/ABL1-like): un apporoccio baato sul target molecolare Sabina Chiaretti, MD PhD LE SFIDE DELLA MEDICINA DI PRECISIONE IN EMATOLOGIA Bologna 28 Giugno, 2018 Topics: BCR/ABL1-like and other subgroups
More informationCase 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX
Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME
More informationRisk Stratification in Childhood Leukemia
Risk Stratification in Childhood Leukemia Why is risk stratification important? Toxicities Deepa Bhojwani, MD May 11, 2018 To determine intensity of therapy - When to intensify therapy - When to de-intensify
More informationPAX5-JAK2 fusion in acute lymphoblastic leukaemia. Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne
PAX5-JAK2 fusion in acute lymphoblastic leukaemia Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne Case 12-year-old girl Diagnosed with BCP ALL in November 2015 Presenting WCC 35x10
More informationETP - Acute Lymphoblastic Leukaemia
ETP - Acute Lymphoblastic Leukaemia Dr Sally Campbell - Royal Children s Hospital Melbourne 24 February 2017 T-ALL 12-15% of all newly diagnosed ALL cases in pediatrics are T-ALL T-ALL behaves differently
More informationDevelopment of Precision Medicine Therapies for Pediatric Acute Lymphoblastic Leukemia Korean Society of Hematology Meeting March 31, 2018
Development of Precision Medicine Therapies for Pediatric Acute Lymphoblastic Leukemia Korean Society of Hematology Meeting March 31, 2018 Stephen P. Hunger, M.D. Chief, Division of Pediatric Oncology
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More informationDR. MULLIGHAN HAS NOTHING TO DISCLOSE
Advances in the genetics of B-progenitor acute lymphoblastic leukemia Charles Mullighan Member, Department of Pathology St Jude Children s Research Hospital Society for Hematopathology Companion Meeting
More informationHandout for lecture on lymphoblastic neoplasms presented by Rob McKenna
Handout for lecture on lymphoblastic neoplasms presented by Rob McKenna The following slides represent a near final version of the presentation that will be given in Maui, January 23,2018. Minor changes
More informationPediatric Treatment Approaches for Adolescent and Young Adult Acute Lymphoblastic Leukemia
Pediatric Treatment Approaches for Adolescent and Young Adult Acute Lymphoblastic Leukemia 2017 Texas Adolescent and Young Adult (TAYA) Oncology Conference Elizabeth Raetz, MD Acute Lymphoblastic Leukemia
More informationALK Fusion Oncogenes in Lung Adenocarcinoma
ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of
More informationBCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures
Published Ahead of Print on June 4, 2015, as doi:10.3324/haematol.2015.124941. Copyright 2015 Ferrata Storti Foundation. BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between
More informationTreatment of High-risk Acute Lymphoblastic Leukemia With Precision Medicine
Treatment of High-risk Acute Lymphoblastic Leukemia With Precision Medicine Minimal Residual Leukemia Level: Independent Prognostic Indicator Leukemic cell Tumor burden Growth potential Drug resistance
More informationTargetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Original Article Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia K.G. Roberts, Y. Li, D. Payne Turner, R.C. Harvey, Y.-L. Yang, D. Pei, K. McCastlain, L. Ding, C. Lu, G. Song,
More informationControversies in Hematology: Case-Based Discussion. Acute leukemia in Adolescents and Young adults October 2018, Chiang Mai Thailand
Controversies in Hematology: Case-Based Discussion Acute leukemia in Adolescents and Young adults 25-26 October 2018, Chiang Mai Thailand Associate Prof. Adisak Tantiworawit, MD Division of Hematology,
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More informationCURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of )
Leukemia AALL0932 closed after Induction CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 10.10.2017) Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
More informationCelebrating 20 years of the Database Joint UKCCG and CHO Annual Conference. 22 nd -23 rd March 2012 Newcastle upon Tyne
Celebrating 20 years of the Database Joint UKCCG and CHO Annual Conference 22 nd -23 rd March 2012 Newcastle upon Tyne The following years. FISH and genomics Christine Harrison Chair, UK Cancer Cytogenetics
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationTSLP-induced Mechanisms and Potential Therapies for CRLF2 B-cell Acute Lymphoblastic Leukemia
Loma Linda University TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works Loma Linda University Electronic Theses, Dissertations & Projects 6-2015 TSLP-induced Mechanisms
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationMP BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
Medical Policy BCBSA Ref. Policy: 2.04.85 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 8.01.30 Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationNews Release. Title Integrated molecular profiling of juvenile myelomonocytic leukemia
News Release Title Integrated molecular profiling of juvenile myelomonocytic leukemia Key Points We identified ALK/ROS1 tyrosine kinase fusions (DCTN1-ALK, RANBP2-ALK, and TBL1XR1-ROS1) in patients with
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationCase #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...
Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationJAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
Degryse and Cools Journal of Hematology & Oncology (2015) 8:91 DOI 10.1186/s13045-015-0192-7 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH HIGHLIGHT JAK kinase inhibitors for the treatment of acute lymphoblastic
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More informationADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW
ADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW Danièle SOMMELET European Scientific Seminar Luxemburg, 3.11.2009 1 Definition of acute leukemias Malignant process coming from lymphoid (85 %)
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationExamining Genetics and Genomics of Acute Myeloid Leukemia in 2017
Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction
More informationNUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia
Case 0094 NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Jessica Snider, MD Medical University of South Carolina Case Report - 64 year old Caucasian Male Past Medical History Osteoarthritis
More informationPhiladelphia chromosome-positive acute lymphoblastic leukemia in childhood
Review article DOI: 10.3345/kjp.2011.54.3.106 Korean J Pediatr 2011;54(3):106-110 Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood Hong Hoe Koo, M.D., Ph.D. Department of Pediatrics,
More informationPediatric Acute Lymphoblastic Leukemia. Highlights of ASH 2015
Pediatric Acute Lymphoblastic Leukemia Highlights of ASH 2015 Thai National Protocol Outcomes Outcome is very dependent on treatment Patient s compliance Treatment of ALL Induction Intensification Maintenance
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091534 Age 36 Years Gender Female 1/9/2017 120000AM 1/9/2017 105316AM 2/9/2017 104147AM Ref By Final LEUKEMIA GENETIC ROFILE ANY SIX MARKERS, CR QUALITATIVE AML ETO
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationCase Report RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic Leukemia
Case Reports in Hematology Volume 2015, Article ID 353247, 6 pages http://dx.doi.org/10.1155/2015/353247 Case Report RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationRUNX1 and FPD/AML Translational Research. The Leukemia and Lymphoma Society / Babich Family Foundation Partnership. September 2016
www.lls.org www.runx1.com RUNX1 and FPD/AML Translational Research The Leukemia and Lymphoma Society / Babich Family Foundation Partnership September 2016 Prepared by L. Greenberger, PhD Chief Scientific
More informationTCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations.
Supplementary Figure 1 TCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations. The CpG motifs closest to the breakpoints are highlighted in red boxes and the
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationStructural modeling of JAK1 mutations in T-ALL reveals a second contact site between pseudokinase and kinase domains
Published Ahead of Print on January 27, 2016, as doi:10.3324/haematol.2015.138248. Copyright 2016 Ferrata Storti Foundation. Structural modeling of JAK1 mutations in T-ALL reveals a second contact site
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23
More informationSeptember 20, Submitted electronically to: Cc: To Whom It May Concern:
History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).
More informationFunctional characterization and targeting of CRLF2 gene alerations in pediatric High Risk Acute Lymphoblastic Leukemia
PhD Program in Molecular and Translational Medicine DIMET (XXVII cycle, year 2013-2014) University of Milano-Bicocca Department of Biotechnologies and Biosciences Functional characterization and targeting
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA
ONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA 1Rosline H, 1Majdan R, 1Wan Zaidah A, 1Rapiaah M, 1Selamah G, 2A A Baba, 3D M Donald 1Department of Haematology, 2Department
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More informationCARE at ASH 2014 Leukemia. Julie Bergeron, MD Maisonneuve-Rosemont Hospital
CARE at ASH 2014 Leukemia Julie Bergeron, MD Maisonneuve-Rosemont Hospital Acute Leukemias Dr. Julie Bergeron Hôpital Maisonneuve-Rosemont, Montréal Disclosures Advisory boards in 2014: AMGEN EUSA pharma
More informationRelapse Cytogenetics Overview of ALLR3 genetics Introduction to the IntReALL trial. Anthony V Moorman Leukaemia Research Cytogenetics Group
Relapse Cytogenetics Overview of ALLR3 genetics Introduction to the IntReALL trial Anthony V Moorman Leukaemia Research Cytogenetics Group Overview of ALLR3 Parker et al, Lancet 2010; 376: 2009 17 Mitoxantrone
More informationMRD in ALL: Correct interpretation in clinical practice. Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh
MRD in ALL: Correct interpretation in clinical practice Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh Minimal residual disease Subclinical level of residual leukemia Below
More informationPhiladelphia-like B-cell precursor acute lymphoblastic leukemia (Ph-like
ARTICLE Acute Lymphoblastic Leukemia EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation Adults with Philadelphia chromosome like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations,
More informationChronic Myeloid Leukemia Outlook: The Future of CML Therapy
Chronic Myeloid Leukemia Outlook: The Future of CML Therapy Neil Shah, MD PhD Edward S. AgenoDistinguished Professor in Hematology/Oncology UCSF School of Medicine San Francisco, California Progression
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): The authors have presented data demonstrating activation of AKT as a common resistance mechanism in EGFR mutation positive, EGFR TKI resistant
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationGenomic Characterization of Acute Leukemias
Review Received: November 3, 2013 Accepted: April 10, 2014 Published online: June 20, 2014 Genomic Characterization of Acute Leukemias Sabina Chiaretti Valentina Gianfelici Giulia Ceglie Robin Foà Division
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Roberts KG, Li Y, Payne Turner D, et al. Targetable kinase-activating
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationSummary. Olga Zając, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak. Rep Pract Oncol Radiother, 2007; 12(5):
Rep Pract Oncol Radiother, 2007; 12(5): 283-288 Preliminary Communication Received: 2007.03.27 Accepted: 2007.07.24 Published: 2007.10.18 Authors Contribution: A Study Design B Data Collection C Statistical
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationApplication of Whole Genome Microarrays in Cancer: You should be doing this test!!
Application of Whole Genome Microarrays in Cancer: You should be doing this test!! Daynna Wolff, Ph.D. Director, Cytogenetics and Genomics Disclosures Clinical Laboratory Director and Employee, Medical
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationFAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 8 COG-AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More informationActivation of cellular proto-oncogenes to oncogenes. How was active Ras identified?
Dominant Acting Oncogenes Eugene E. Marcantonio, M.D. Ph.D. Oncogenes are altered forms of normal cellular genes called proto-oncogenes that are involved in pathways regulating cell growth, differentiation,
More informationRedefining Patient Care in Acute Lymphoblastic Leukemia: The Impact of Novel Antibody and Immune Technologies on Clinical Outcomes
CME Redefining Patient Care in Acute Lymphoblastic Leukemia: The Impact of Novel Antibody and Immune Technologies on Clinical Outcomes Course Director and Moderator Daniel J. DeAngelo, MD, PhD Harvard
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationFuture of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
Future of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Primitive sleeping BCR-ABL-positive leukemic stem cells are less
More informationPRECURSOR LYMHPOID NEOPLASMS. B lymphoblastic leukaemia/lymphoma T lymphoblastic leukaemia/lymphoma
PRECURSOR LYMHPOID NEOPLASMS B lymphoblastic leukaemia/lymphoma T lymphoblastic leukaemia/lymphoma B lymphoblastic leukaemia/lymphoma Definition: B lymphoblastic leukaemia/lymphoma is a neoplasm of precursor
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationAcute Lymphoblastic Leukaemia Guidelines
Acute Lymphoblastic Leukaemia Guidelines Approved by Pathway Board for Haematological Malignancies Coordinating author: Adele Fielding, Royal Free London NHS Trust Date of issue: 12.03.2015 Version number:
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More informationESMO DOUBLE-HIT LYMPHOMAS
ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in
More informationPacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018
Pacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018 Outline Case study Introduction of Current management of infantile
More informationExtramedullary precursor T-lymphoblastic transformation of CML at presentation
Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More informationEVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib
EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib Mustafa Daghistani Department of Haematology, Imperial College London at Hammersmith Hospital, Du Cane Road,
More informationGENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA
CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationHaematology Probes for Multiple Myeloma
Haematology Probes for Multiple Myeloma MULTIPLE MYELOMA Multiple myeloma (MM) is a plasma cell neoplasm, characterised by the accumulation of clonal plasma cells in the bone marrow and by very complex
More informationSALSA MLPA probemix P383-A1 T-ALL Lot A
SALSA MLPA probemix P383-A1 T-ALL Lot A1-0213. T-lineage acute lymphoblastic leukaemia (T-ALL) is a clonal malignant disorder of immature T-cells, which accounts for about 15% of paediatric and 25% of
More informationJAK2 V617F analysis. Indication: monitoring of therapy
JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationFrontiers in Cancer Therapy. John Glod, M.D., Ph.D.
Frontiers in Cancer Therapy John Glod, M.D., Ph.D. September 15, 2017 Objectives The Past: Alkylating agents The Present: Tyrosine Kinase Inhibitors The Future: Gene Expression, Metabolic cancers, CAR
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationMolecular Advances in Hematopathology
Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important
More informationIdentifying therapeutic targets by elucidating signaling pathways in pediatric lymphoid leukemias van der Sligte, Naomi Eline
University of Groningen Identifying therapeutic targets by elucidating signaling pathways in pediatric lymphoid leukemias van der Sligte, Naomi Eline IMPORTANT NOTE: You are advised to consult the publisher's
More informationTemplate for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+)
Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+) Version: CMLBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is
More informationLymphoblastic Leukemia / Lymphoma
1 5014 - Topics in Pediatric Hematopathology: Acute Lymphoblastic Leukemia, Including Changes in the Revised WHO Classification, and Unusual Pediatric Myeloid Neoplasms Robert W. McKenna, MD MASCP * Elizabeth
More informationChapter 4 Cellular Oncogenes ~ 4.6 -
Chapter 4 Cellular Oncogenes - 4.2 ~ 4.6 - Many retroviruses carrying oncogenes have been found in chickens and mice However, attempts undertaken during the 1970s to isolate viruses from most types of
More information